Pfizer Zeldox Approval Awaits QTc Comparison To Risperdal, Zyprexa
Executive Summary
Pfizer will compare the QTc interval prolongation of its antipsychotic Zeldox to Lilly's Zyprexa (olanzapine) and Janssen's Risperdal (risperidone) as a condition for approval.
You may also be interested in...
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Labeling for Pfizer's Zeldox (ziprasidone) should clearly warn against combination use with other drugs that may prolong the QTc interval, but a black box may not be necessary, FDA's Psychopharmacological Drugs Advisory Committee suggested July 19.